Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The latest announcement is out from Jazz Pharmaceuticals ( (JAZZ) ).
On August 10, 2026, Jazz Pharmaceuticals agreed to acquire privately held Actio Biosciences in a deal featuring an $820 million upfront payment and up to $500 million in milestone-based contingent consideration. The transaction, unanimously approved by both boards and expected to close by the fourth quarter of 2026, will be financed through Jazz’s cash on hand and existing credit facilities.
The acquisition brings Actio’s lead asset ABS-1230, a first-in-class KCNT1 ion channel inhibitor for ultra-rare KCNT1+ epilepsy, which has no approved therapies and causes profound, treatment-resistant seizures and severe developmental impairment. ABS-1230 has shown meaningful seizure reductions in early trials, carries multiple FDA rare-disease designations and is part of the FDA’s RDEP program, reinforcing Jazz’s leadership in rare epilepsy and expanding its pipeline, while a concurrent spinout will leave Actio’s other genetic neurology assets in a new private company in which Jazz will hold a minority stake.
The most recent analyst rating on (JAZZ) stock is a Buy
with a $300.00 price target.
To see the full list of analyst forecasts on Jazz Pharmaceuticals stock,
see the JAZZ Stock Forecast page.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Outperform.
JAZZ scores well primarily on improving financial quality (strong free cash flow and reduced leverage) and a positive earnings-call setup (raised guidance and strong commercial execution). Technicals also support the score with an established uptrend. The key offset is valuation, with an extremely high P/E and no dividend yield provided.
To see Spark’s full report on JAZZ stock,
click here.
More about Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharma company focused on developing life-changing medicines for patients with rare diseases, often where therapeutic options are limited or nonexistent. Its diversified portfolio spans treatments for epilepsies, cancers and sleep disorders, underpinned by a robust pipeline and commercial strength in rare and severe epilepsy, including the Epidiolex franchise.
Actio Biosciences is a clinical-stage biotechnology company that translates Mendelian genetic insights into small molecule precision medicines for rare diseases with high unmet need and potential expansion into more prevalent indications. Its lead programs include ABS-1230 for KCNT1-related epilepsy and ABS-0871 for Charcot-Marie-Tooth disease type 2C and other TRPV4-related neuromuscular disorders, with broader applications such as additional genetic epilepsies and overactive bladder.
Average Trading Volume: 865,883
Technical Sentiment Signal: Buy
Current Market Cap: $16.65B
For detailed information about JAZZ stock, go to TipRanks’ Stock Analysis page.